Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model A multistate model for Ewing sarcoma

被引:19
|
作者
Bosma, S. E. [1 ]
Rueten-Budde, A. J. [2 ]
Lancia, C. [2 ]
Ranft, A. [3 ,4 ]
Dirksen, U. [3 ,4 ]
Krol, A. D. [5 ]
Gelderblom, H. [6 ]
van de Sande, M. A. J. [1 ]
Dijkstra, P. D. S. [1 ]
Fiocco, M. [2 ,7 ]
机构
[1] Leiden Univ, Med Ctr, Dept Orthoped, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[2] Leiden Univ, Math Inst, Leiden, Netherlands
[3] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Sarcoma Ctr,German Canc Consortium,Pediat 3, Essen, Germany
[4] German Canc Consortium DKTK, Essen, Germany
[5] Leiden Univ, Med Ctr, Dept Radiotherapy, Leiden, Netherlands
[6] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands
[7] Leiden Univ, Med Ctr, Med Stat Biomed Data Sci, Leiden, Netherlands
基金
欧盟第七框架计划;
关键词
Ewing sarcoma; multistate model; personalized medicine; prediction; survival; PROGNOSTIC-FACTORS; CHEMOTHERAPY; TUMORS; BONE; EXPERIENCE; SURVIVAL; ADJUVANT; SURGERY; THERAPY; PROGRAM;
D O I
10.1002/pbc.27943
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We investigated the effects of surgical margins, histological response, and radiotherapy on local recurrence (LR), distant metastasis (DM), and survival in Ewing sarcoma. Procedure Disease evolution was retrospectively studied in 982 patients with Ewing sarcoma undergoing surgery after chemotherapy using a multistate model with initial state surgery, intermediate states LR, pulmonary metastasis (DMpulm), other DM +/- LR (DMother), and final state death. Effect of risk factors was estimated using Cox proportional hazard models. Results The median follow-up was 7.6 years (95% CI, 7.2-8.0). Risk factors for LR are pelvic location, HR 2.04 (1.10-3.80), marginal/intralesional resection, HR 2.28 (1.25-4.16), and radiotherapy, HR 0.52 (0.28-0.95); for DMpulm the risk factors are <90% necrosis, HR 2.13 (1.13-4.00), and previous pulmonary metastasis, HR 4.90 (2.28-8.52); for DMother are 90% to 99% necrosis, HR 1.56 (1.09-2.23), <90% necrosis, HR 2.66 (1.87-3.79), previous bone/other metastasis, HR 3.08 (2.03-4.70); and risk factors for death without LR/DM are pulmonary metastasis, HR 8.08 (4.01-16.29), bone/other metastasis, HR 10.23 (4.90-21.36), and <90% necrosis, HR 6.35 (3.18-12.69). Early LR (0-24 months) negatively influences survival, HR 3.79 (1.34-10.76). Once DMpulm/DMother arise only previous bone/other metastasis remain prognostic for death, HR 1.74 (1.10-2.75). Conclusion Disease extent and histological response are risk factors for progression to DM or death. Tumor site and surgical margins are risk factors for LR. If disease progression occurs, previous risk factors lose their relevance. In case of isolated LR, time to recurrence is important for decision-making. Radiotherapy seems protective for LR especially in pelvic/axial. Low percentages of LR in extremity tumors and associated toxicity question the need for radiotherapy in extremity Ewing sarcoma.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Local recurrence of Ewing sarcoma: Is wide excision an acceptable treatment?
    Xue, Ruifeng
    Lewis, Valerae O.
    Moon, Bryan S.
    Lin, Patrick P.
    JOURNAL OF SURGICAL ONCOLOGY, 2019, 120 (04) : 746 - 752
  • [2] Risk of Recurrence and Survival After Relapse in Patients With Ewing Sarcoma
    Stahl, Martin
    Ranft, Andreas
    Paulussen, Michael
    Boelling, Tobias
    Vieth, Volker
    Bielack, Stefan
    Goertitz, Irene
    Braun-Munzinger, Gabriele
    Hardes, Jendrik
    Juergens, Heribert
    Dirksen, Uta
    PEDIATRIC BLOOD & CANCER, 2011, 57 (04) : 549 - 553
  • [3] Risk analysis factors for local recurrence in Ewing's sarcoma WHEN SHOULD ADJUVANT RADIOTHERAPY BE ADMINISTERED?
    Albergo, J. I.
    Gaston, C. L. L.
    Parry, M. C.
    Laitinen, M. K.
    Jeys, L. M.
    Tillman, R. M.
    Abudu, A. T.
    Grimer, R. J.
    BONE & JOINT JOURNAL, 2018, 100B (02): : 247 - 255
  • [4] Risk Factors for Metastasis at Initial Diagnosis With Ewing Sarcoma
    Ye, Conglin
    Dai, Min
    Zhang, Bin
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [5] The patterns of distant metastasis and prognostic factors in patients with primary metastatic Ewing sarcoma of the bone
    Zhang, Lei
    Xiong, Lu
    Wu, Li-Mei
    Shen, Wen-Hui
    Zhou, Ping
    Lian, Chen-Lu
    Zhang, Wen-Tong
    Wu, San-Gang
    JOURNAL OF BONE ONCOLOGY, 2021, 30
  • [6] Risk factors for metastasis and poor prognosis of Ewing sarcoma: a population based study
    Shi, Jiaqi
    Yang, Jianing
    Ma, Xin
    Wang, Xu
    JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH, 2020, 15 (01)
  • [7] A Visualized Dynamic Prediction Model for Lymphatic Metastasis in Ewing's Sarcoma for Smart Medical Services
    Li, Wenle
    Xu, Chan
    Hu, Zhaohui
    Dong, Shengtao
    Wang, Haosheng
    Liu, Qiang
    Tang, Zhi-Ri
    Li, Wanying
    Wang, Bing
    Lei, Zhi
    Yin, Chengliang
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [8] Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma
    Lin, Patrick P.
    Jaffe, Norman
    Herzog, Cynthia E.
    Costelloe, Colleen M.
    Deavers, Michael T.
    Kelly, Jeana S.
    Patel, Shreyaskumar R.
    Madewell, John E.
    Lewis, Valerae O.
    Cannon, Christopher P.
    Benjamin, Robert S.
    Yasko, Alan W.
    CANCER, 2007, 109 (03) : 603 - 611
  • [9] Development and Validation of a Novel Clinical Prediction Model to Predict the Risk of Lung Metastasis from Ewing Sarcoma for Medical Human-Computer Interface
    Li, Wenle
    Hong, Tao
    Xu, Chan
    Wang, Bing
    Hu, Zhaohui
    Liu, Qiang
    Wang, Haosheng
    Dong, Shengtao
    Kang, Wei
    Yin, Chengliang
    COMPUTATIONAL INTELLIGENCE AND NEUROSCIENCE, 2022, 2022
  • [10] A Machine Learning-Based Predictive Model for Predicting Lymph Node Metastasis in Patients With Ewing's Sarcoma
    Li, Wenle
    Zhou, Qian
    Liu, Wencai
    Xu, Chan
    Tang, Zhi-Ri
    Dong, Shengtao
    Wang, Haosheng
    Li, Wanying
    Zhang, Kai
    Li, Rong
    Zhang, Wenshi
    Hu, Zhaohui
    Shibin, Su
    Liu, Qiang
    Kuang, Sirui
    Yin, Chengliang
    FRONTIERS IN MEDICINE, 2022, 9